Wanted: A Platform for Tissue Based Biomarker Discovery

Wanted: A Platform for Tissue Based Biomarker Discovery
Access to tissue based biomarkers has become key to cancer research, patient stratification in conjunction with clinical trials, and for companion diagnostics. In the context of cancer research and biomarker discovery, Tissue microarrays (TMAs) has ...
Read more

Automation and Increased Accuracy for Hormone Receptors in Breast Cancer

Automation and Increased Accuracy for Hormone Receptors in Breast Cancer
Join Visiopharm next week for a webinar titled, “Hormone Receptors in Breast Cancer: Automation and Increased Accuracy” on September 16, 2014 at 4 PM CET / 10 AM EST / 7 AM PST. Estrogen (ER) and progesterone (PR; PgR) evaluation is routinely use...
Read more

Visiopharm Fully Automated APP for Ki67 Assessment in Breast Cancer CE Marked for In-Vitro Diagnostic Use in Europe

Visiopharm Fully Automated APP for Ki67 Assessment in Breast Cancer CE Marked for In-Vitro Diagnostic Use in Europe
The Virtual Double Staining (VDS) Ki67 module for breast is a novel, patented and now CE-marked diagnostic APP intended for automated tumor/stroma separation and computation of the Ki67 labelling index for the identified tumor cells. The Visiopharm ...
Read more

Stereology Explained in Only 3.5 Minutes

One of our customers, Gubra a biotech company delivering pre-clinical contract research services within obesity and diabetes, created this excellent infographic video on Stereology.   If you have always wanted to know more about or underst...
Read more

The Importance of Quality HER2 Testing for Breast Cancer

Genentech released a great, simple to understand, infographic video that illustrates the importance of quality with regard to HER2 for breast cancer with a 5 step process.  The 5 steps are: The Basics of HER2 Follow the Sample The Most Com...
Read more

The Market Development Fund Supports Visiopharm to Improve Cancer Diagnostics Across Europe

Today, the Market Development Fund, announced that it will support Visiopharm’s validation of its novel solutions for cancer diagnostics at seven Danish Hospitals and three international Hospitals. Visiopharm’s diagnostic solution Oncotopix Dx...
Read more